QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Antitumor Virotherapy Platform Data at Three Scientific Conferences
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is set to present data on its innovative systemic antitumor virotherapy platform, RTNova (CLD-400), at multiple scientific conferences. These include the International Oncolytic Virotherapy Conference in Rotterdam (Oct. 27-30), the Immuno US 2024 in San Diego (Oct. 28-29), and the Society for Immunotherapy of Cancer Annual Meeting in Houston (November 6-10). RTNova is designed to address the challenges posed by untargetable and untreatable metastatic diseases by targeting multiple tumor sites and altering the tumor immune microenvironment. This approach not only facilitates easier administration but also broadens the potential patient population who…